Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer
| Autor: | Mauri, D., Polyzos, N. P., Salanti, G., Pavlidis, Nicholas, Ioannidis, J. P. A. |
|---|---|
| Přispěvatelé: | Pavlidis, Nicholas [0000-0002-2195-9961], Surgical clinical sciences, Faculty of Medicine and Pharmacy |
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
Oncology
Cancer Research Antimetabolites medicine.medical_treatment Anthracyclines/therapeutic use Anthracycline Deoxycytidine Targeted therapy Breast cancer Antibiotics Controlled clinical trial Antineoplastic Combined Chemotherapy Protocols Antineoplastic agents breast neoplasms Odds Ratio Anthracyclines Treatment outcome Middle aged Anthracycline derivative Randomized Controlled Trials as Topic Priority journal Survival time Antibiotics Antineoplastic Odds ratio Middle Aged Statistical Antimetabolites Antineoplastic/therapeutic use Chemotherapy regimen Antineoplastic Antineoplastic Agents/*therapeutic use Clinical trial Bevacizumab Breast Neoplasms/*drug therapy/*mortality/pathology Taxoids/administration & dosage Treatment Outcome Antibiotics Antineoplastic/therapeutic use Research design Research Design Randomized controlled trial Data Interpretation Statistical Female Taxoids Fluorouracil medicine.drug Human Adult medicine.medical_specialty Antimetabolites Antineoplastic Antineoplastic Agents CAPECITABINE Cancer mortality Lapatinib Vinorelbine Article Low drug dose Randomized controlled trials as topic Internal medicine Antineoplastic combined chemotherapy protocols Fluorouracil/administration & dosage/analogs & derivatives medicine Deoxycytidine/administration & dosage/analogs & derivatives Humans Capecitabine Aged Taxane business.industry Data interpretation Taxane derivative Survival analysis Trastuzumab medicine.disease Monotherapy Survival Analysis Gemcitabine FLUOROURACIL Surgery Cancer combination chemotherapy Drug efficacy Systematic review Antineoplastic Combined Chemotherapy Protocols/therapeutic use Breast neoplasms Mitoxantrone business Meta analysis |
| Zdroj: | Journal of the National Cancer Institute |
| ISSN: | 1973-2007 |
| Popis: | Background: Many systemic nonhormonal regimens have been evaluated across several hundreds of randomized trials in advanced breast cancer. We aimed to quantify the relative merits of these regimens in prolonging survival. Methods: We performed a systematic review of all trials that compared different regimens involving chemotherapy and/or targeted therapy in advanced breast cancer (1973-2007). Regimens were categorized a priori into different treatment types. We performed multiple-treatments meta-analysis and calculated hazard ratios for each treatment category relative to monotherapy with old agents (ie, regimens not including anthracyclines, anthracenediones, vinorelbine, gemcitabine, capecitabine, taxanes, marimastat, thalidomide, trastuzumab, lapatinib, or bevacizumab). Results: We identified 370 eligible randomized trials (54 189 patients), of which 172 (31 552 patients) compared different types of treatment. Survival data from 148 comparisons pertaining to 128 of the 172 trials (26 031 patients, 22 different types of treatment) were available for inclusion in the multiple-treatments meta-analysis. Compared with single-agent chemotherapy with old nonanthracycline drugs, anthracycline regimens achieved 22%-33% relative risk reductions in mortality (ie, hazard ratio [HR] for standard-dose anthracycline-based combination: 0.67, 95% credibility interval [CrI] 0.57-0.78). Several newer regimens achieved further benefits (eg, HR [95% CrI] 0.67 [0.55-0.81] for single-drug taxane, 0.64 [0.53-0.78] for combination of anthracyclines with taxane, 0.49 [0.37-0.67] for taxane-based combination with capecitabine or gemcitabine), and similar benefits were seen with several regimens including molecular targeted treatments. Most regimens had very similar efficacy profiles ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|